The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease
Status:
Unknown status
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to assess the effects of rasagiline on cognitive functions in
patient with Parkinson's disease. Patients on any dopaminergic medications will be assigned
to receive rasagiline 1 mg or placebo over 3 months. Cognitive functions will be assessed by
selected neuropsychological tests representing each cognitive domain.